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Aim: Zidovudine and tenofovir form the backbone of antiretroviral therapy in Kenya.
However, their side-effects may affect the quality of life (QoL) of patients. The aim was to
compare the health-related quality of life (HRQoL) of adult patients on tenofovir versus
zidovudine based regimens in a referral hospital in Kenya to provide future guidance.
Methods: A comparative cross sectional study among 501 adult out-patients on either
tenofovir or zidovudine was undertaken in Kenyatta National Hospital between 2015
and 2016. The Medical Outcome Study HIV Health Survey (MOS-HIV) was administered
along with other key aspects of treatment. Linear regression analysis was performed to
identify determinants of HRQoL.
Results: Patients on zidovudine had a higher Physical Health Summary Score (PHSS)
and Mental Health Summary Score (MHSS) compared to those on tenofovir. The
presence of any symptom of the disease and a stated inability to cope were negatively
associated with PHSS, whilst having a regular source of income improved PHSS. Being
on tenofovir, symptom of illness [β = −1.24; 95% CI (−2.253, −0.226)], absence of
pain [β=0.413; 95% CI (0.152, 0.674)] and patient stated inability to cope with HIV
[β = −1.029; 95% CI (−1.441, −0.617)] affected the MHSS. Patients on tenofovir and
second line regimens had more signs and symptoms of illness.
Conclusion: Participants on zidovudine based regimens showed a better performance
across all aspects of HRQoL. These are considerations for the future.
Keywords: HRQoL, MOS-HIV, side-effects, tenofovir, zidovudine, antiretroviral treatments, Kenya
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INTRODUCTION
The World Health Organization defines health as “a state of
complete physical, mental and social well-being and not merely
the absence of disease or infirmity” (WHO Constitution of
The World Health Organization, 2006). Diseases affect the
psycho-social status of an individual by increasing the economic
burden, psychological distress, and social unacceptability of
patients especially with conditions associated with stigma, such
as Human Immunodeficiency Virus (HIV) infection. This non-
physical effect of HIV, and the associated medicines, can lead
to despair and even non-adherence to treatment (Campos et al.,
2009; National AIDS STI Control Programme [NASCOP], 2011).
Consequently, there is a need for studies to evaluate the impact of
treatments on health-related quality of life (HRQoL) especially in
diseases such as HIV associated with stigma, where there are also
concerns with the toxicity of treatments, and inHIV patients with
combined morbidities, to guide future strategies (Oguntibeju,
2012; Balderson et al., 2013; Degroote et al., 2014; Vagiri et al.,
2014, 2015; Rogers, 2015; Mafirakureva et al., 2016; Brandt et al.,
2017).
HIV/AIDS is prevalent in sub-Sahara Africa, accounting for
up to 80% of the world’s HIV infected population, and is a
leading cause of death and morbidity in these countries (National
AIDS STI Control Programme [NASCOP], 2011; Rogers, 2015).
For instance, in Botswana at one stage nearly 50% of women
aged between 30 and 34 years had HIV, which has potential
implications for quality of life (QoL) and adherence to treatments
if patients also have concomitant non-communicable diseases
(Rwegerera et al., 2018). This reflects the greater prevalence of
HIV among women than men in sub-Sahara Africa, different to
the populations typically seen in Western countries (Gaida et al.,
2016; Kalemeera et al., 2016; Ayele et al., 2017a; Mataranyika
et al., 2018). In Kenya, the incidence rate for new HIV infections
was recently estimated at 137,200 with an estimated 1.88 million
patients living with HIV (Wang et al., 2016).
HIV is highly stigmatized to the extent that it may lead
to delayed health seeking behavior, access to treatment and in
some instances suicide (Lieber et al., 2006; Maimaiti et al., 2017;
Cornelius et al., 2018; Wang et al., 2018). Having said this,
access to HIV treatment has appreciably improved in Eastern and
Southern Africa in recent years (Dadi et al., 2017). Opportunistic
infections associated with HIV/AIDS may also cause devastating
psychological distress and decrease the ability of patients
to perform normal duties (Wang et al., 2018). In addition,
antiretroviral (ARV)medicines can appreciably reducemorbidity
and mortality, including significant physical improvement and
associated HRQoL. However, these medicines may also cause
severe side-effects themselves potentially impacting on any
improvement in HRQoL that could be gained through treatment,
though some regimens are becoming more tolerable (Burgoyne
and Tan, 2008; Mannheimer et al., 2008; Campos et al., 2009;
Oguntibeju, 2012; Velen et al., 2013; Dadi et al., 2017; Pasquau
et al., 2018).
Tenofovir is a nucleotide reverse transcriptase inhibitor
(NtRTI), an ARV that is commonly used in combination with
other ARVs in the management of HIV infection in Kenya
and elsewhere as part of the first line regimen (National AIDS
STI Control Programme [NASCOP], 2011). However, it is
associated with side-effects (Subbaraman et al., 2007; Nemaura
et al., 2013; Waheed et al., 2015). Zidovudine is an ARV which
belongs to the class of nucleoside reverse transcriptase inhibitors
(NRTIs) (Velen et al., 2013; Dadi et al., 2017; Ayele et al.,
2017a). Both are widely used in Kenya in combination for the
management of patients with HIV/AIDS (National AIDS STI
Control Programme [NASCOP], 2011).
Zidovudine is used as an alternative to tenofovir in
antiretroviral treatment (ART) regimens, although it is also
associated with side-effects such as chronic anemia, which are
likely to affect patients’ QoL. Tenofovir is claimed to have a better
safety profile compared to zidovudine, with the main side-effect
being renal toxicity (Awino, 2008; Dadi et al., 2017). Some studies
have shown that tenofovir is superior to zidovudine in terms
of its safety profile because of a reduced incidence of anemia
and fat redistribution (Wandeler et al., 2014; Insaniputri et al.,
2017). Other studies have also shown that tenofovir had fewer
side-effects, but the range of side-effects studied was limited
(Saez-Llorens et al., 2015). However, this still remains to be seen
across populations in sub-Sahara Africa.
Currently few studies have been conducted in Kenya on the
HRQoL of people living with HIV who are on ART. This is very
important given the appreciable number of citizens with HIV in
Kenya and concerns with accessing and adhering to treatment
in reality (Wang et al., 2016). Consequently, this study aimed to
compare the HRQoL of adult HIV positive patients on tenofovir
versus zidovudine based regimens and to determine potential
factors that affect HRQoL. In addition, to measure the prevalence
and risk factors for the presence of symptoms of illness or side-
effects in HIV patients. The findings will provide evidence to
influence future treatment selection and policy decisions within
Kenya and wider.
MATERIALS AND METHODS
Design, Study Site, and Population
A comparative cross sectional study was undertaken using
the Medical Outcome Study HIV Health Survey (MOS-HIV)
questionnaire (Wu et al., 1997). The study was conducted
at Kenyatta National Hospital (KNH) Comprehensive Care
Center (CCC). KNH is the main referral and teaching
hospital in Kenya for patients with HIV, and manages
approximately 5,000 of these patients. Consequently, KNH
CCC could provide comprehensive data for assessing these
issues. The study population was adult HIV positive patients
attending the CCC clinic at KNH between December 2015
and May 2016. The patients were either on tenofovir or
zidovudine based regimens. The current Kenyan guidelines
for treatment of HIV (National AIDS STI Control Programme
[NASCOP], 2011) recommend the use of tenofovir, lamivudine,
and efavirenz (TDF+3TC+EFV) as first line therapy
among patients older than 15 years. Previous guidelines
recommended the use of a zidovudine based regimen as first line
therapy.
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TABLE 1 | Baseline socio-demographic characteristics of study participants (n = 501).
Variable Tenofovir (n = 301) Zidovudine (n = 200) Total (n = 501) p-Value
Age (years)
18–35 66 (21.9) 50 (25) 116 (23.2)
36–45 127 (42.2) 86 (43) 213 (42.5)
46–64 104 (34.6) 62 (31) 166 (33.1) 0.809
≥ 65 3 (0.9) 2 (1) 5 (0.9)
Missing 1 (0.3) − 1 (0.2)
Sex n = 501
Male 87 (28.9) 63 (31.5) 150 (29.9)
Female 212 (70.4) 136 (68) 348 (69.5) 0.619
Missing 2 (0.7) 1 (0.5) 3 (0.59)
Marital status
Married 158 (52.5) 106 (53) 264 (52.6)
Married/Cohabiting 3 (0.9) 5 (2.5) 8 (1.6) 0.332
Single 61 (20.3) 33 (16.5) 94 (18.8)
Widowed 46 (15.3) 26 (13) 72 (14.4)
Divorced 33 (10.9) 29 (14.5) 62 (12.4)
Missing − 1 (0.5) 1 (0.2)
Regions
Nyanza 75 (24.9) 36 (18) 111 (22.2)
Western 49 (16.3) 28 (14) 77 (15.4)
Rift valley 13 (4.3) 12 (6) 25 (4.9)
Nairobi 6 (1.9) 4 (2) 10 (1.9) 0.537
Central 89 (29.6) 62 (31) 151 (30.1)
Eastern North 55 (18.3) 48 (24) 103 (20.5)
Eastern 5 (1.7) 3 (1.5) 8 (1.6)
Coast 5 (1.7) 4 (2) 9 (1.8)
Missing 4 (1.3) 3 (1.5) 7 (1.4)
HIV status disclosure
Yes 232 (77.1) 158 (79) 390 (77.8) 0.433
No 67 (22.3) 38 (19) 105 (20.9)
Missing 2 (0.4) 4 (2) 6 (1.2)
Educational level
No education 7 (2.3) 2 (1) 9 (1.8)
Primary 53 (17.6) 48 (24) 101 (20.2)
Secondary 144 (47.8) 90 (45) 234 (46.7)
Tertiary/University 95 (31.6) 55 (27.5) 150 (29.9) 0.121
Others 0 (0) 2 (1) 2 (0.4)
Missing 2 (0.7) 3 (1.5) 5 (0.9)
Religious belief
No 4 (1.3) 1 (0.5) 5 (0.9)
Yes 294 (97.7) 197 (98.5) 491 (98) 0.653
Missing 3 (0.9) 2 (1) 5 (0.9)
Regular source of income
No 66 (21.9) 38 (19) 104 (20.8) 0.572
Yes 232 (77.1) 155 (77.5) 387 (77.3)
Missing 3 (0.9) 7 (3.5) 10 (1.9)
Sample Size Considerations and Sampling
The Lui’s (1991) formula was used for sample size computation,
as this was a two arm comparative study with a continuous
outcome variable. The population variance of HRQoL was
assumed to be 22.5, as obtained from a study conducted by Mast
et al. (2004). The difference in the HRQoL between the two
groups was assumed to be 2, the level of significance was set
at 0.05 and therefore the standard normal deviate used in the
formula was 1.96. The power of the study (1-β) was set at 90%,
hence the conventional multiplier for power was 1.282. Using this
formula, the calculated minimal sample size was 217 per arm.
This figure was inflated by 10% to compensate for non-responses.
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TABLE 2 | Baseline medical history of participants on tenofovir and zidovudine based regimens (n = 501).
Variable Tenofovir (n = 301) Zidovudine (n = 200) Total (n = 501) p-Value
Duration of HIV infection in years
≤2.0 39 (13) 5 (2.5) 44 (8.8)
2.1–5.0 70 (23.3) 46 (23) 116 (23.2)
5.1–10.0 124 (41.2) 113 (56.5) 237 (47.3)
10.1–15.0 49 (16.3) 25 (12.5) 74 (14.8) <0.001
>15 19 (6.3) 10 (5) 29 (5.8)
Missing − 1 (0.5) 1 (1.2)
Duration on ART in years
≤1.0 35 (11.6) 3 (1.5) 38 (7.6)
1.1–2.0 30 (10) 7 (3.5) 37 (7.4)
2.1–5.0 82 (27.2) 62 (31) 144 (28.7)
5.1–10 121 (40.2) 111 (55.5) 232 (46.3) <0.001
>10 33 (11) 16 (8.0) 49 (9.8)
Missing − 1 (0.5) 1 (0.2)
Adherence: Missed drug intake
Missing 6 (2.0) 1 (0.5) 7 (1.4)
No 195 (64.8) 142 (71) 337 (67.3) 0.187
Yes 100 (33.2) 57 (28.5) 157 (31.3)
Recent CD4+ count in cells/mm3
<250 41 (13.6) 37(18.5) 78 (15.6)
250–499 108 (35.9) 71 (35.5) 179 (35.7)
500–999 127 (42.2) 73 (36.5) 200 (39.9) 0.414
≥1000 15 (4.9) 9 (4.5) 24 (4.8)
Missing 10 (3.3) 10 (5) 20 (3.9)
Recent viral load copies/ml n = 158
0.01 62 (70.5) 45 (64.3) 107 (67.7)
1–1000 14 (15.9) 7 (10) 21 (13.3) 0.121
>1000 12 (13.6) 18 (25.7) 30 (19)
NB: Bold under p-value denotes statistical significance.
TABLE 3 | ART regimens of study participants at Kenyatta National Hospital (n = 501).
Variable AZT-based regimens (n, %) TDF-based regimens (n, %) Total (n, %)
Type of ART regimen
AZT/3TC/NVP 89 (17.8) TDF/3TC/NVP 65 (12.9)
AZT/3TC/EFV 82 (16.4) TDF/3TC/EFV 218 (43.5)
AZT/3TC/LPV/r 21 (4.2) TDF/3TC/LPV/r 17 (3.4)
AZT/3TC/ATV/r 8 (1.6) TDF/3TC/ATV/r 1 (0.2)
Total 200 (39.9) Total 301(60.1)
Participants on selected drugs (n, %)
EFV 82 (41) 218 (72.4) 300 (59.9)
NVP 89 (44.5) 65 (21.6) 154 (30.7)
LPV/r 21 (10.5) 17 (5.7) 38 (7.6)
ATV/r 8 (4) 1 (0.3) 9 (1.8)
Total 200 (100) 301 (100) 501 (10.0)
First line therapy 171 (85.5) 283 (94.0) 454 (90.6)
Second line therapy 29 (14.5) 18 (6.0) 47 (9.4)
NB: TDF-Tenofovir, 3TC-Lamivudine, EFV-Efavirenz, NVP-Nevirapine, LPV/r-Lopinavir/ritonavir, ATV/r-Atazanavir/ritonavir, DRV/r-Duranavir/ritonavir, AZT-zidovudine.
The final calculated sample size was 238 per arm (Lui, 1991):
2N = [4(Zα/2+ Z1−β)
2σ2]/δ2
Where:
Zα/2 = the standard normal deviate at 95% CI (1.96)
Z1−β = the Z-value corresponding to a power of 90 (1.282)
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TABLE 4 | Coping mechanisms of the study participants and satisfaction with service provided.
Variable Tenofovir (n = 301) Zidovudine (n = 200) Total (n = 501) p-Value
Coping strategy
Acceptance 104 (34.6) 50 (25) 154 (30.7) 0.034
Sharing about illness 93 (30.8) 84 (42) 177 (35.3)
Support group 87 (28.9) 60 (30) 147 (29.3)
Spiritual support 13 (4.3) 6 (3) 19 (3.8)
Any other 3 (0.9) 0 (0) 3 (0.6)
Missing 1 (0.3) − 1 (0.2)
Satisfaction with service provision
Very good 195 (64.8) 144 (72) 339 (67.7)
Good 96 (31.9) 47 (23.5) 143 (28.5) 0.138
Fair 8 (2.7) 8 (4) 16 (3.2)
Bad 1 (0.3) 1 (0.5) 2 (0.4)
Missing 1 (0.3) − 1 (0.2)
Alcoholism/substance dependence
Use alcohol 87 (28.9) 54 (27) 141 (28.1)
Hard drugs 5 (1.7) 5 (2.5) 10 (1.9) 0.704
No drugs 202 (67.1) 139 (69.5) 341 (68.1)
Missing 7 (2.3) 2 (1) 9 (1.8)
NB: Bold under p-value denotes statistical significance.
Eligibility Criteria and Participant
Recruitment
Adult patients of either sex who gave informed consent, and
who had been on either tenofovir or zidovudine based regimens
for at least 6 months, were included in the study. Patients were
recruited during their clinic days. Those who consented were
recruited within the pharmacy as they were collecting their
medicines.
A total of 6 months was chosen for the inclusion criteria
because longitudinal studies have shown significant changes in
QoL of patients who started on ART after this period, regardless
of the CD4+ count (Subbaraman et al., 2007). For this reason,
patients who had been on therapy for less than 6 months were
deliberately excluded. Individuals who were expectant mothers
or those who did not meet the inclusion criteria were also
excluded.
Data Collection Tool, Patient Interview,
and Abstraction of Patient Records
The MOS-HIV questionnaire was used to collect data on HRQoL
since unlike other tools for assessing HRQoL in HIV patients,
it was specifically designed to collect information on patient
reported symptoms in HIV positive patients. In addition, the
physical and mental health aspects of HRQoL are separately
measured using this tool. It has also been extensively used in
a wide variety of settings with consistent reliability and validity
(Mast et al., 2004), and has been validated in a study in Uganda,
which has a similar cultural background as Kenya. In the
Ugandan study, the tool was found to have good construct- and
face validity and reliability (Mast et al., 2004).
Research assistants together with the principal investigator
collected the data. The research assistants were trained nurses
who worked within the Comprehensive Care Clinic where the
data was collected. Patients report to the clinic every 3 months.
Approximately 10 patients were seen daily during the study
period. To ensure confidentiality, only one participant was
interviewed at a time in the pharmacy consultation room before
they collected their medicines.
The MOS-HIV questionnaire was administered to
participants during the interview. Additional information
on socio-demographic characteristics, symptoms participants
were experiencing, satisfaction with service provision, coping
mechanisms, adherence tomedication, and alcoholism/substance
dependence were also obtained during the interview using
additional questions that were not part of the MOS-HIV
questionnaire (Wu et al., 1997; Mast et al., 2004). Data on
the recent CD4+ count and viral load was extracted from the
patients’ records.
Computation of the Scores of Individual
Domains of Health
The raw scores of each of the domains were computed as
described in the MOS-HIV Health Survey User’s Manual (Wu
et al., 1991, 1997). All the items and scales were scored so that a
higher score indicated better health. 11 items were reverse coded
because a higher pre-coded item value indicated a poorer health
state. This ensured that a higher value indicated better health on
all MOS-HIV items and scales.
Each of the questions entailed responses that had a value which
ranged from 1 to 2, 1 to 4, and 1 to 6, based on the Likert scale.
The sum of the scores of the responses from the questions in a
particular domain were taken as the raw score.
The scores were subsequently transformed to a scale of 0–100.
Higher score values represented a better HRQoL while a lower
score indicated poorer HRQoL. The method for transformation
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TABLE 5 | Comparison of the prevalence of symptoms across the regimens.
Type of symptom Tenofovir (n, %) Zidovudine (n, %) Total (n, %) p-Value
Presence of any symptom
Missing 2 (0.7) 3 (1.5) 5 (1.0) 0.005
No 241 (80.6) 178 (90.4) 419 (84.5)
Yes 58 (19.4) 19 (9.6) 77 (15.5)
Pain 17 (5.7) 3 (1.5) 20 (4.0) 0.015
Weight 12 (3.99) 2 (1) 14 (2.8) 0.038
Skin disorder
Has a Skin disorder 11 (3.7) 6 (3.0) 17 (3.4) 0.609
No skin disorder 288 (95.7) 191 (95.5) 484 (95.6)
Missing data 2 (0.7) 3 (1.5) 5 (1.0)
Type of kind disorder
Skin pigmentation 2 (0.7) 1 (0.5)
Wound 1 (0.3) 2 (1)
Skin rash 1 (0.3) 1 (0.5)
Itching 2 (0.7) 1 (0.5)
Ear peeling 1 (0.3) 0 (0)
Pimples 1 (0.3) 0 (0)
Mouth sours 1 (0.3) 0 (0)
Wound in private part 1 (0.3) 0 (0)
Herpes 1 (0.3) 0 (0)
Unspecified skin problem 0 (0.3) 1 (0.5)
Psychological problems
Emotional 1 (0.3) 1 (0.5) 2 (0.4) 0.360
Loss of concentration and fatigue 1 (0.3) 0 (0.0) 1 (0.2)
Liver problem
Yellow eyes 1 (0.3) 0 (0.0) 1 (0.2) 0.216
Yellow eyes and swollen legs 2 (0.7) 0 (0.0) 2 (0.4)
Musculoskeletal
Limping 2 (0.7) 0 (0.0) 2 (0.4) 0.476
Cannot walk 0 (0.0) 1 (0.5) 1 (0.2)
Change in physical structure 1 (0.3) 0 (0.0) 1 (0.2)
Others
Tiredness 1 (0.3) 1 (0.5) 2 (0.4) 0.640
Bad breath 0 (0.0) 1 (0.5) 1 (0.2) 0.432
Stroke 1 (0.3) 0 (0.0) 1 (0.2) 0.57
Blindness 0 (0.0) 1 (0.5) 1 (0.2) 0.432
Colds 5 (1.7) 0 (0.0) 5 (1.0) 0.061
Eye problem 1 (0.3) 0 (0.0) 1 (0.2) 0.57
Swollen legs 1 (0.3) 0 (0.0) 1 (0.2) 0.57
Swollen neck 1 (0.3) 0 (0.0) 1 (0.2) 0.57
NB: Bold under p-value denotes statistical significance.
of the scores is described in the MOS questionnaire user’s manual
(Wu et al., 1991).
Computation of the Physical- and the
Mental Health Summary Score
The scores for each domain were used to obtain both the
Physical Health Summary Scores (PHSS) and the Mental
Health Summary Scores (MHSS). Z-score transformation
for standardization of the scores to the standard Roche
patient population was undertaken as described in the MOS
questionnaire user’s manual (Wu et al., 1991). The Roche patient
population was a group of HIV positive patients on whom
validation of the MOS-HIV tool was performed (Wu et al.,
1997).
The obtained PHSS and MHSS were subsequently
transformed to have a mean of 50 and a SD of 10 in order
to obtain the final PHSS and MHSS as described in the
MOS-HIV manual (Wu et al., 1997).
Data Management and Quality
Assurance
Data was entered in an Epi Info Version 7 database within
24 h after completion of the questionnaire. Evaluation
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TABLE 6 | Risk factors for any symptom of disease or side-effects.
Variable Crude OR (95% CI) p-Value Adjusted OR (95% CI) p-Value
Socio-demographic
Age 0.98 (0.959,1.010) 0.239 –
Gender 1.37 (0.782,2.389) 0.272 –
Married 0.813 (0.499,1.322) 0.404 –
Region 0.998 (0.886,1.124) 0.976 –
Had disclosed status 1.024 (0.562,1.864) 0.939 –
Education level 1.01 (0.739,1.390) 0.933 –
Regular source of income 0.990 (0.543,1.806) 0.974 –
Baseline medical characteristics
HIV duration 1.008 (0.956,1.063) 0.774 –
ART duration 0.981 (0.916,1.051) 0.586 –
Missed drug intake 1.345 (0.811,2.231) 0.251 –
Recent CD4+ Count 0.999 (0.999,1.000) 0.276 –
Recent viral load 1.0 (0.999,1.000) 0.446 –
Drug-related factors
Zidovudine 0.480 (0.278,0.827) 0.008 –
Tenofovir 2.084 (1.209,3.595) 0.008 2.385 (1.356, 4.194) 0.003
Nevirapine 0.540 (0.300,0.971) 0.040 –
Efavirenz 1.130 (0.685,1.864) 0.632 –
Lopinavir/ritonavir 2.520 (1.188,5.341) 0.016 –
Atazanavir/ritonavir 1.570 (0.320,7.701) 0.579 –
First line regimen 0.421 (0.210,0.843) 0.015 –
Second line regimen 2.376 (1.187,4.757) 0.015 2.977 (1.443, 6.144) 0.003
Regiment 1.244 (1.090,1.419) 0.001 –
NB: Bold under p-value denotes statistical significance.
FIGURE 1 | Comparison of Physical Health Summary Score between zidovudine and tenofovir based regimens.
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TABLE 7 | Regression analysis of determinants of Physical Health Summary Score (PHSS).
Variable Crude beta coefficient (95% CI) p-Value Adjusted beta coefficient (95% CI) p-Value
ART regimen (TDF vs. AZT) 2.04 (0.58,3.50) 0.006 −
Sex −2.04 (−3.46,−0.62) 0.005 −1.986 (−3.460,−0.511) 0.008
Age −0.05 (−0.13,0.03) 0.223 −
Age above 40 −1.46 (−2.83,−0.08) 0.038 −1.782 (−3.202,−0.361) 0.014
Religious belief 2.62 (−4.78,10.03) 0.487 −
Education level 0.55 (−0.47,1.56) 0.294 −
Status disclosure 1.93 (−0.24,4.10) 0.081 −
Region −0.03 (−0.37,0.31) 0.856 −
Has regular source of income 3.07 (0.75,5.39) 0.010 2.617 (0.456,4.778) 0.018
Marital status −0.54 (−1.01,0.07) 0.025 −
HIV disease
HIV duration 0.04 (−0.13,0.21) 0.617 −
ART duration 0.10 (−0.12,0.31) 0.380 −
Recent CD4+ cells/mm3 0.003 (−0.0003,0.006) 0.079 −
Recent viral load copies/ml 7.99e−08 (−5.80e−07,7.40e−07) 0.811 −
ART medications
Missed drugs intake −1.39 (−3.04,0.27) 0.100
Zidovudine 2.025 (0.564,3.485) 0.007 1.329 (0.002,2.657) 0.050
Nevirapine 0.48 (−1.037,1.996) 0.534 −
Efavirenz 0.78 (−0.739,2.298) 0.314 −
Lopinavir/ritonavir −4.30 (−8.194,−0.403) 0.031 −3.773 (−7.418,−0.129) 0.042
Atazanavir/ritonavir −0.26 (−6.4,5.87) 0.932 −
First line regimen 3.64 (0.205,7.074) 0.038 −
Second line regimen −3.64 (−7.074,−0.205) 0.038 −
Coping mechanism
Satisfaction with service
provision
−0.89 (−2.08,0.29) 0.140 −
Unable to cope with HIV −1.92 (−2.79,−1.05) <0.001 −1.813 (−2.562,−1.064) < 0.001
Substance dependence −0.22 (−0.75,0.31) 0.411 −
Joined support group −0.357 (−2.655,1.941) 0.760 −
Sharing with others −0.229 (−2.128,1.669) 0.813 −
Spiritual support −0.004 (−2.067,2.058) 0.997 −
Acceptance of status 0.202 (−2.055,2.460) 0.860 −
Has signs and symptoms of
illness or adverse reaction
Reported any symptom −6.57 (−9.35,−3.79) <0.001 −5.581 (−8.072,−3.091) < 0.001
Has weight disorder −4.154 (−9.751,1.444) 0.145 −
Type of weight disorder −1.53 (−3.941,0.881) 0.213 −
Has skin disorder −1.94 (−6.325,2.446) 0.388 −
Has pain −8.802 (−13.994,−3.610) 0.001 −
NB: Bold under p-value denotes statistical significance.
for completeness and accuracy was undertaken daily and
data backed-up weekly. Confidentiality was maintained
by using patient codes instead of identifier information.
Training and explanation of the nature of the study was
undertaken with the research assistants prior to the study.
Pre-testing of the questionnaire was undertaken on 20 patients
with subsequent refinement of the actual questionnaire.
This only related to the data collection section on socio-
demographic characteristics, CD4+ counts, and patient-related
symptoms.
Variables and Statistical Analysis
The three dependent variables were PHSS, MHSS and the
prevalence of symptoms of disease/side-effects. Independent
variables were ARV regimens, socio-demographic traits, and
HIV-related history.
Descriptive statistics were used and the Shapiro–Wilk test
performed to test whether continuous variables were normally
distributed. They were summarized using the median and the
interquartile range. Categorical variables were summarized as
counts and percentages.
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FIGURE 2 | Comparison of Mental Health Summary Score between participants on zidovudine and tenofovir based regimens.
Distribution of all variables was compared across the two
groups using inferential tests which included Chi-square,
Mann–Whitney, and un-paired Student’s t-tests. Logistic
regression analysis was used to identify the risk factors for any
symptoms of disease or side-effects. Linear regression with robust
estimation was conducted to identify predictors of the MHSS and
PHSS. Model building was undertaken using a forward stepwise
approach. The level of significance was set at 0.05. STATA version
10.0 was used for data analysis.
Ethical Considerations
Ethical approval was obtained from Kenyatta National
Hospital/University of Nairobi (KNH/UoN) Ethics and
Research Committee (Approval Reference Number: KNH-
ERC/A/467). Institutional approval was sought from KNH.
Informed consent was obtained from patients. Privacy was
maintained by conducting the interview in a secluded room.
Confidentiality was maintained by using codes instead of patient
identifier information.
RESULTS
Participants’ Baseline
Socio-Demographic Characteristics
A total of 501 patients were recruited. Most (60.8%) of the
patients were on tenofovir based regimens. Most were female
(348; 69.5%) and were aged between 36 and 45 years. Less than
half of the participants (234; 46.7%) had attained secondary level
education and approximately half were married. Most patients
(77.8%) had disclosed their HIV status to at least a friend or
relative. There were no statistically significant differences in the
socio-demographic traits across the two arms (Table 1).
Baseline Medical Characteristics of
Study Participants
There was a statistically significant difference in the duration of
HIV infection and the duration on ART (p < 0.001) across the
two arms. Those patients on zidovudine had been on treatment
longer as zidovudine was the first line regimen before tenofovir
was introduced. A total of 47.3% had been HIV positive for
5.1 to 10 years and 44.7% had a CD4+ count of > 500 cells/mm3
and above.
Out of the participants who had a viral load report, 67.7% had
a viral load of less than 0.01 copies/ml. 21.6% of participants in
the tenofovir arm had been on therapy for 2 years and below
compared to only 5% in the zidovudine arm. In the tenofovir
arm, 11% of the participants had been on treatment for more
than 10 years compared to only 8% in the zidovudine arm. The
CD4+ counts and adherence were comparable across the arms.
The baseline medical characteristics of study participants are
presented in Table 2.
Antiretroviral Treatment Regimens of the
Participants
The majority of the participants were on a first line regimen
compared to only 9.4% on a second line regimen. Most of
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TABLE 8 | Bi-variable regression analysis – determinants of Physical Health
Summary Score.
Variable Crude beta Coefficient 95% CI p-Value
Patient regimen 1.12 (0.47,1.76) 0.001
Sex −0.58 (−1.28,0.13) 0.111
Age 0.03 (−0.01,0.07) 0.148
Religious belief −0.24 (−3.35,2.87) 0.877
Education level −0.04 (−0.47,0.39) 0.859
Status disclosure 0.4 (−0.46,1.26) 0.360
Region −0.01 (−0.17,0.15) 0.895
Has regular source
of income
0.42 (−0.58,1.43) 0.410
Marital status −0.16 (−0.39,0.06) 0.159
Married − –
HIV duration −0.02 (−0.10,0.06) 0.616
ART duration −0.04 (−0.14,0.06) 0.467
Any symptom
compromising
HRQoL
−2.0 (−3.13,−0.85) 0.001
Satisfaction with
service provision
−0.89 (−1.49,−0.29) 0.004
Inability to cope
with HIV
−1.12 (−1.58,−0.66) <0.001
Missed drugs
intake
−0.26 (−1.0,0.48) 0.486
Alcoholism/substance
dependence
0.075 (−0.16,0.31) 0.528
Recent CD4+
cells/mm3
0.001 (−0.001,0.002) 0.308
Recent viral load
copies/ml
2.93e−07(1.60e−07,4.24e−07) <0.001
Zidovudine 1.063 (0.417,1.710) 0.001
Nevirapine 0.394 (−0.306,1.093) 0.269
Efavirenz −0.121 (−0.793,0.552) 0.725
Lopinavir/ritonavir −0.739 (−1.971,0.493) 0.239
Atazanavir/ritonavir −4.437 (−2.325,1.451) 0.649
First line 0.701 (−0.384,1.786) 0.205
Second line −0.701 (−1.786,0.384) 0.205
Type of skin
disorder
−0.264 (−0.557,0.030) 0.078
Type of weight
disorder
−1.401 (−2.152,−0.650) <0.001
Type of pain −1.144 (−1.721,−0.568) <0.001
Regimen −0.261 (−0.410,−0.111) 0.001
Has pain −3.77 (−6.481,−1.052) 0.007
Has weight problems −2.76 (−4.126,−1.39) <0.001
Has skin problem −1.087 (−3.499,1.324) 0.376
NB: Bold under p-value denotes statistical significance.
the participants were on TDF/3TC/EFV (43.5%). The ratio of
participants on tenofovir to zidovudine was 6:4 (Table 3).
All the study participants were on lamivudine, irrespective
of whether they were on tenofovir or zidovudine. Out
of 47 patients on second line therapy, the majority (29)
were on zidovudine while 18 were on tenofovir. Most
patients on tenofovir based regimens were on efavirenz as
opposed to the zidovudine based arm where most were on
nevirapine.
TABLE 9 | Bi-variable regression analysis – variables associated with the Mental
Health Summary Score.
Variable Crude beta Coefficient (95% CI) p-Value
Sex −0.58 (−1.28,0.13) 0.111
Age 0.03 (−0.01,0.07) 0.148
Education level −0.04 (−0.47,0.39) 0.859
Region −0.01 (−0.17,0.15) 0.895
Marital status −0.16 (−0.39,0.06) 0.159
Has regular source of
income
0.42 (−0.58,1.43) 0.410
HIV Disease
HIV duration −0.02 (−0.10,0.06) 0.616
ART duration −0.04 (−0.14,0.06) 0.467
Recent CD4+ cells/mm3 0.001 (−0.001,0.002) 0.308
Recent viral load
copies/ml
2.93e−07(1.60e−07,4.24e−07) <0.001
ART medications
Regimen (TDF vs. AZT) −0.261 (−0.410,−0.111) 0.001
Nevirapine 0.394 (−0.306,1.093) 0.269
Efavirenz −0.121 (−0.793,0.552) 0.725
Lopinavir/ritonavir −0.739 (−1.971,0.493) 0.239
Atazanavir/ritonavir −4.437 (−2.325,1.451) 0.649
Second line regimen −0.701 (−1.786,0.384) 0.205
Missed drugs intake −0.26 (−1.0,0.48) 0.486
Has signs and
symptoms of illness or
adverse reaction
Reported any
symptoms/signs
−2.0 (−3.13,−0.85) <0.001
Has skin problem −1.087 (−3.499,1.324) 0.376
Type of skin disorder −0.264 (−0.557,0.030) 0.078
Has weight problems −2.76 (−4.126,−1.39) <0.001
Type of weight disorder −1.401 (−2.152,−0.650) <0.001
Has pain −3.77(−6.481,−1.052) 0.007
Type of pain disorder −1.144 (−1.721,−0.568) <0.001
Inability to cope with HIV −1.12 (−1.58,−0.66) <0.001
Ability to cope and
coping mechanisms
Joined support group −0.029 (−0.951,0.892) 0.950
Sharing with others 0.297 (−0.367,0.961) 0.380
Spiritual support −0.176 (−0.927,0.575) 0.645
Acceptance of status 0.250 (−0.933,1.434) 0.678
Status disclosure 0.4 (−0.46,1.26) 0.360
Substance dependence 0.075 (−0.16,0.31) 0.528
Coping Mechanisms and Satisfaction
With Services Provided
Nearly a third of the participants embraced sharing about their
illness as a coping style (35.3%). The majority of the participants
were very satisfied with the quality of service offered by the
health care providers. Nearly, a third (28.1%) of participants took
alcohol to help with coping.
There was a significant difference (p = 0.034) in the type
of coping mechanisms across the regimens. Participants
on tenofovir had accepted their HIV status while those on
zidovudine adopted sharing about their illness to help them
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to cope. When compared to the tenofovir arm, slightly
more participants on zidovudine had joined a support
group. The coping mechanisms adopted are summarized in
Table 4.
Prevalence of Adverse Symptoms of
Disease and Side-Effects
The overall prevalence of any adverse signs and symptoms
including side-effects was 15.5%. Five (1%) of the participants did
not give a response. There was a statistically significant difference
in the prevalence of adverse symptoms and side-effects across the
two arms (p = 0.005).
Out of the participants who had symptoms and side-effects
that compromised their HRQoL, 57 (74.0%) patients were on
tenofovir and 20 (26%) were on zidovudine based regimens.
We did not differentiate whether symptoms were as a result
of the disease or the side-effects of treatment as the goal is to
improve health outcomes of patients on ART while minimizing
adverse events. The majority of the patients reported no skin
disorder (96.2%) (Table 5). Where these were reported, the
most common skin disorders were skin pigmentation and
wounds.
There was a statistically significant difference in the prevalence
of pain- and weight-related symptoms in patients on zidovudine
versus tenofovir based regimens (p = 0.015 and 0.038),
respectively. The most common type of disorder among all the
participants was pain, at 4%, with patients on tenofovir having a
higher prevalence of pain (5.7%) (Table 5). The sources of pain
were backache (n = 8; 1.6%), headache (n = 4; 0.8%), chest pain
(n = 3; 0.6%), general body pain (n = 3; 0.6%), as well as breast
and leg pain (n = 2; 0.4%).
The second most common disorder was weight-related
changes at 2.8% of all participants in the study. Nearly 4%
of participants on tenofovir had a weight-related problem as
opposed to only 1% of participants on zidovudine, which was
statistically significant (p = 0.038; Table 5). The most common
weight-related problem was weight loss (1.8%). With regard
to skin problems, three patients had skin pigmentation, two
patients had skin rash, three had itching, and one patient
each had ear peeling, pimples, oral sores, genital wounds, and
herpes. Three had unspecified skin problems. Only one patient
complained of each of the following symptoms: bad breath,
blindness, swollen legs, swollen neck, and eye problems. Two
patients reported chronic fatigue (0.4%) and 5 (1%) had cold-like
symptoms.
Risk Factors for Any Symptom of
Disease or Side-Effects
The risk factors for presence of any symptom were being on
tenofovir as well as second line regimens, which remained
statistically significant when adjusting for confounding (Table 6).
Comparison of Physical Health Summary
Scores of Patients on Tenofovir and
Zidovudine
Participants in the zidovudine based arm had a higher median
score regarding physical activity (61.90; IQR: 59.55–62.82)
compared to those on the tenofovir based regimens (60.14; IQR:
55.11–62.26) (Figure 1).
A regular source of income was associated with a 2.62 unit
[95% CI (0.456, 4.778)] increase in the PHSS. Being on a
zidovudine based regimen also improved the PHSS by 1.33 units
[95% CI (0.002, 2.66)] (Table 7).
Having a symptom that compromises HRQoL greatly reduced
the PHSS by −5.58 [95% CI (−8.072, −3.091)] units. This
association remained statistically significant even after adjusting
for confounding for type of regimen, stable income, sex, and
age. Patients who complained of pain had a lower PHSS than
those who did not [crude beta coefficient −8.802, 95% CI
(−13.994, −3.610)]. This finding was statistically significant
(p = 0.001), though was confounded by the type of regimen and
lost significance in the multivariable analysis because participants
on TDF-based regimens were more likely to complain of pain.
Weight changes had no statistical significant impact on PHSS
though we noted a negative association. Other factors that
reduced the PHSS were female gender [β = −1.986; 95% CI
(−3.460, −0.511)], age above 40 [β = −1.782; 95% CI (−3.202,
−0.361)], inability to cope with HIV [β = −1.813; 95% CI
(−2.562,−0.064)], and being on lopinavir/ritonavir (β =−3.773;
95% CI (−7.418,−0.129)] (Table 7) .
Determinants and Predictors of the
Summary Scores (PHSS and MHSS)
Participants on zidovudine based regimens had a higher median
MHSS (51.83; IQR: 50.38–53.70) compared to 51.30 (IQR:
48.39–53.08) of those on the tenofovir based arm, with Figure 2
comparing the MHSS of participants on zidovudine versus
tenofovir based regimens.
Bivariate regression analysis showed that being on an ART
regimen (p = 0.001), having any symptom that compromises
TABLE 10 | Parsimonious models of the Mental Health Summary Score of study participants.
Variable Most parsimonious model Parsimonious model in which
regimen is replaced by AZT
Model adjusted for
duration of ART use
Stated inability to cope with HIV −0.999 (−1.411,−0.588) −0.995 (−1.407,−0.582) −1.029 (−1.441,−0.617)
Absence of pain 0.413 (0.152,0.674) 0.413 (0.152,0.674) 0.414 (0.154,0.675)
Presence of any symptom of illness −1.240 (−2.253,−0.226) −1.28 (−2.293,−0.266) −1.238 (−2.246,−0.230)
Types of ART Regimen −0.187 (−0.330,−0.045) − −0.205 (−0.346,−0.063)
If patient was on AZT − 0.738 (0.127,1.349) −
Duration of ART use − − −0.081 (−0.179,0.017)
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HRQoL (p = 0.001), satisfaction with service provision
(p = 0.004), inability to cope with HIV (p < 0.001), and the
availability of recent viral load data (p < 0.001) all affected the
HRQoL of patients (Table 8). The presence of any symptoms
that compromised the HRQoL was negatively related to the PHSS
[β = −2.0; 95% CI (−3.13, −0.85); p < 0.001]. The patient stated
inability to cope with HIV was attributed to a reduction in the
PHSS by−1.12 units [95% CI (−1.58,−0.66)].
Pain and weight changes had a negative significant effect
on the MHSS as presented in Table 9. However, the effect of
weight changes lost significance on multivariable analysis. After
adjusting for confounding for the duration of illness and the type
of regimen, the influence of any symptom of an adverse reaction
remained significant (Table 10).
Overall, the presence of any symptom reduced the MHSS
by 1.24 units [95% CI (−2.253, −0.226)] before adjusting for
confounders (Table 10). This association remained significant
even after adjusting for confounding by duration of ART use.
The absence of pain score increased the MHSS by 0.413 units
[95% CI (0.152, 0.674)] and this association was not confounded
by the duration of therapy and being on zidovudine. Being on
zidovudine based regimens was also associated with improved
mental health with β = 0.738 [95% CI (0.127, 1.349)].
DISCUSSION
Patients on zidovudine based regimens appeared to have a
better HRQoL score compared to those on tenofovir based
regimens aided by less adverse events and side-effects. The risk
factors for the presence of adverse symptoms and side-effects
were being on tenofovir or second line regimens. We were not
aware of studies that have directly compared the HRQoL of
patients on the two regimens, although studies have compared
other outcomes and overall cost-effectiveness between the two
regimens (von Wyl et al., 2012; Velen et al., 2013; Ayele et al.,
2017a,b). Consequently, we believe this is probably the first
study in this area, and certainly we believe within sub-Saharan
Africa.
However, our findings appear to contradict a number of
other studies that have assessed the two regimens in terms of
their safety and clinical outcomes, which have reported better
outcomes and tolerability with tenofovir. A systematic review
and meta-analysis of the efficacy and tolerability of the tenofovir
based regimen (TDF/3TC/EFV) and the zidovudine based
regimen (AZT/3TC/EFV) by Dadi et al. reported better outcomes
for TDF/3TC/EFV when compared to AZT/3TC/EFV (Dadi
et al., 2017). Velen et al. also reported better performance with
tenofovir based regimens as opposed to zidovudine regimens
(Velen et al., 2013). We are not sure of the reasons behind these
differences; however, we will be exploring this further in future
studies. Our postulation is that different sample sizes among the
studies could have played a role.
There was a positive correlation between a regular source of
income and improved PHSS, which is similar to a number of
studies illustrating that HRQoL is positively related to income
(Mafirakureva et al., 2016). As a result, a range of efforts should
be put in programs in order to improve the QoL in HIV patients
(Van Tam et al., 2012; Vagiri et al., 2014). This is in addition
to instigating treatments that can improve symptoms without
appreciable toxicity. This is because the side-effects of treatment
as well as adverse symptoms greatly reduce both PHSS and the
MHSS, and hence HRQoL.
The overall prevalence of adverse symptoms and side-effects
in our study (Tables 5, 6) was low (15.5%), and much lower that a
previous study conducted at Kiambu sub-county among persons
living with HIV, reporting a 65.2% prevalence of symptoms
suggestive of ADRs (Nderitu et al., 2013). This is important as
the side-effects of therapy can greatly reduce adherence to ART
even if they are provided free-of-charge to patients (Nderitu
et al., 2013). The prevalence of any symptoms in our study
was 15.5%, similar to that previously seen among HIV patients
with opportunistic infections in the same hospital (Awino,
2008).
Participants on the tenofovir based arm had a higher
prevalence of symptoms or side-effects and consequently had
a lower HRQoL compared to those on zidovudine. Previous
pharmacovigilance studies on ADRs, conducted among patients
in developing countries, also reported side-effects associated with
tenofovir (Subbaraman et al., 2007; Nemaura et al., 2013;Waheed
et al., 2015). The risk factors for the presence of symptoms
or side-effects in this study were being on tenofovir or second
line regimens. This is important for guiding future treatment
strategies in sub-Saharan countries such as Kenya.
Among the participants, 15.5% reported a symptom which
ranged from pain, dermatological reactions, and confusion.
Regression analysis confirmed that presence of any symptom
had a negative effect on both the PHSS and MHSS. Following
regression analysis, this reduced the physical health of patients by
−6.05 (−8.61, −3.49) units while the mental health was reduced
by −1.85 (−2.72, −0.98) units. This concurs with a number
of studies that have demonstrated negative effects of signs or
symptoms of illness on QoL (Dadi et al., 2017; Pasquau et al.,
2018). For instance, a study on the effects on ART in the public
sector in South Africa by Wouters et al. highlighted the need for
clinicians to be vigilant about the adverse effects of treatment
since these can have severe effects on both physical and emotional
QoL (Wouters et al., 2009).
We are aware this study had limitations. First, the subjective
nature of the questionnaire implies that some of the claims
by the patients could not be verified; however, arguably,
using patient’s self-reported HRQoL could be considered a
strength since patient HRQoL is a subjective phenomenon
and can only be reported directly by the patient, i.e., it
cannot be observed and therefore not reported by a clinician
or caregiver. We are also aware that the study did not
clearly differentiate the symptoms of the disease with the side-
effects of the treatment. In addition, by default, the numbers
of participants on tenofovir based regimens were greater
than those on the zidovudine based regimen in accordance
with the Kenyan treatment guidelines. This study was also
only conducted at one city and center in Kenya. Having
said this, we believe the study had a comparatively large
sample size making it reasonably representative of the patient
Frontiers in Pharmacology | www.frontiersin.org 12 October 2018 | Volume 9 | Article 984
Etenyi et al. HRQoL Zidovudine and Tenofovir Based Regimens
population with HIV in Kenya. In addition, KNH is the tertiary
center where patients with HIV in Kenya come to be treated.
The study also highlighted the need to evaluate the patients
rating of their own health, with the key components of health
being physical and mental health as perceived by patients,
which were evaluated in this study. The use of the disease
specific MOS-HIV questionnaire enables the findings to be
compared to other studies where similar questionnaires are
used. Consequently, we believe our findings are robust providing
direction for the future.
CONCLUSION
Patients on zidovudine had better PHSS and MHSS compared
to those on tenofovir based regimens. However, we believe
additional studies are required to confirm these findings,
especially in view of the differences seen in our study versus
others regarding the side-effects of treatment with these two
treatments, before definitive guidance can be given on which
regimens to preferentially use. These are considerations for
the future, and we will be progressing this research in our
hospital.
AUTHOR CONTRIBUTIONS
JE, FO, SO, and GO designed the concept of the study, undertook
the analysis, and with JE led the interview team. AK, JM, and BG
also helped with the analysis. JE, SO, JM, MO, and BG developed
the first draft of the manuscript. All the authors contributed to
the successive refinements and approved the final version before
submission.
FUNDING
This study was in part supported by a Newton Institutional
Links grant awarded to MO by the Academy of Medical
Sciences, through the United Kingdom Government’s Newton
Fund program.
REFERENCES
Awino, M. (2008). Prevalence and Management of Opportunistic Infections in
HIV-Infected Children. Available at: http://erepository.uonbi.ac.ke/
Ayele, T., Jarso, H., and Mamo, G. (2017a). Clinical outcomes of tenofovir
versus zidovudine-based regimens among people living with HIV/AIDS: a
two years retrospective cohort study. Open AIDS J. 11, 1–11. doi: 10.2174/
1874613601711010001
Ayele, T., Jarso, H., and Mamo, G. (2017b). Immunological outcomes of Tenofovir
versus Zidovudine-based regimens among people living with HIV/AIDS: a two
years retrospective cohort study. AIDS Res. Ther. 14:5. doi: 10.1186/s12981-
017-0132-4
Balderson, B. H., Grothaus, L., Harrison, R. G., McCoy, K., Mahoney, C.,
Catz, S., et al. (2013). Chronic illness burden and quality of life in an
aging HIV population. AIDS Care 25, 451–458. doi: 10.1080/09540121.2012.
712669
Brandt, C., Zvolensky, M. J., Woods, S. P., Gonzalez, A., Safren, S. A., O’Cleirigh,
C. M., et al. (2017). Anxiety symptoms and disorders among adults living
with HIV and AIDS: a critical review and integrative synthesis of the
empirical literature. Clin. Psychol. Rev. 51, 164–184. doi: 10.1016/j.cpr.2016.
11.005
Burgoyne, R. W., and Tan, D. H. (2008). Prolongation and quality of life for HIV-
infected adults treated with highly active antiretroviral therapy (HAART): a
balancing act. J. Antimicrob. Chemother. 61, 469–473. doi: 10.1093/jac/dkm499
Campos, L. N., Cesar, C. C., and Guimaraes, M. D. (2009). Quality of life among
HIV-infected patients in Brazil after initiation of treatment. Clinics 64, 867–875.
doi: 10.1590/S1807-59322009000900007
Cornelius, L. J., Erekaha, S. C., Okundaye, J. N., and Sam-Agudu, N. A. (2018).
A socio-ecological examination of treatment access, uptake and adherence
issues encountered by HIV-positive women in rural North-Central Nigeria.
J. Evid. inf. Soc. Work 15, 38–51. doi: 10.1080/23761407.2017.1397580
Dadi, T. L., Kefale, A. T., Mega, T. A., Kedir, M. S., Addo, H. A., and Biru,
T. T. (2017). Efficacy and tolerability of tenofovir disoproxil fumarate based
regimen as compared to zidovudine based regimens: a systematic review and
meta-analysis. AIDS Res. Treat. 2017:5792925. doi: 10.1155/2017/5792925
Degroote, S., Vogelaers, D., and Vandijck, D. M. (2014). What determines health-
related quality of life among people living with HIV: an updated review of the
literature. Arch. Public Health 72:40. doi: 10.1186/2049-3258-72-40
Gaida, R., Truter, I., Grobler, C., Kotze, T., and Godman, B. (2016). A review
of trials investigating efavirenz-induced neuropsychiatric side effects and the
implications. Expert Rev. Anti Infect. Ther. 14, 377–388. doi: 10.1586/14787210.
2016.1157469
Insaniputri, P., Supardi, S., and Andrajati, R. (2017). Comparison of zidovudine
combination and tenofovir combination on the effectiveness of therapy and side
effects in HIV/AIDS patients in rsal mintohardjo. Asian J. Pharm. Clin. Res. 10,
93–96. doi: 10.22159/ajpcr.2017.v10s5.23107
Kalemeera, F., Mbango, C., Mubita, M., Naikaku, E., Gaida, R., and Godman, B.
(2016). Effect of changing from first- to second-line antiretroviral therapy on
renal function: a retrospective study based on data from a single health facility
in Namibia. Expert Rev. Anti Infect. Ther. 14, 777–783. doi: 10.1080/14787210.
2016.1202759
Lieber, E., Li, L., Wu, Z., Rotheram-Borus, M. J., and Guan, J. (2006). HIV/STD
stigmatization fears as health-seeking barriers in China. AIDS Behav. 10,
463–471. doi: 10.1007/s10461-005-9047-5
Lui, K. J. (1991). Sample size determination in case-control studies. J. Clin.
Epidemiol. 44, 609–612. doi: 10.1016/0895-4356(91)90225-X
Mafirakureva, N., Dzingirai, B., Postma, M. J., van Hulst, M., and Khoza, S. (2016).
Health-related quality of life in HIV/AIDS patients on antiretroviral therapy
at a tertiary care facility in Zimbabwe. AIDS Care 28, 904–912. doi: 10.1080/
09540121.2016.1173639
Maimaiti, R., Yuexin, Z., Kejun, P., Wubili, M., Lalanne, C., Duracinsky, M., et al.
(2017). Assessment of health-related quality of life among people living with
HIV in Xinjiang, West China. J. Int. Assoc. Provid. AIDS Care 16, 588–594.
doi: 10.1177/2325957417729752
Mannheimer, S. B., Wold, N., Gardner, E. M., Telzak, E. E., Huppler Hullsiek, K.,
Chesney, M., et al. (2008). Mild-to-moderate symptoms during the first year of
antiretroviral therapy worsen quality of life in HIV-infected individuals. Clin.
Infect. Dis. 46, 941–945. doi: 10.1086/528859
Mast, T. C., Kigozi, G., Wabwire-Mangen, F., Black, R., Sewankambo, N.,
Serwadda, D., et al. (2004). Measuring quality of life among HIV-
infected women using a culturally adapted questionnaire in Rakai
district, Uganda. AIDS Care 16, 81–94. doi: 10.1080/0954012031000163
3994
Mataranyika, P. A., Kibuule, D., Kalemeera, F., Kaura, H., Godman, B., and Rennie,
W. T. (2018). Liver enzyme elevations in a cohort of HIV/AIDS patients on first-
line antiretroviral therapy in Namibia: findings and implications Alex. J. Med.
54, 49–56. doi: 10.1016/j.ajme.2017.03.002
National AIDS STI Control Programme [NASCOP] (2011). Guidelines for
Antiretroviral therapy in Kenya. Available at: http://guidelines.health.go.ke:
8000/media/Final_guidelines_re_print_11-09-2012.pdf
Frontiers in Pharmacology | www.frontiersin.org 13 October 2018 | Volume 9 | Article 984
Etenyi et al. HRQoL Zidovudine and Tenofovir Based Regimens
Nderitu, W. F., Gikonyo, N., and Sinei, K. A. (2013). Detection and management
of adverse drug reactions related to antiretroviral drugs among HIV/AIDS
patients in kiambu sub-county, Kenya. East Cent. Afr. J. Pharm. Sci. 16,
3–12.
Nemaura, T., Dhoro, M., Nhachi, C., Kadzirange, G., Chonzi, P., and
Masimirembwa, C. (2013). Evaluation of the prevalence, progression
and severity of common adverse reactions (Lipodystrophy, CNS,
peripheral neuropathy, and hypersensitivity reactions) associated with
Anti-Retroviral Therapy (ART) and anti-tuberculosis treatment in outpatients
in Zimbabwe. J. AIDS Clin. Res. 4:203. doi: 10.4172/2155-6113.100
0203
Oguntibeju, O. O. (2012). Quality of life of people living with HIV and
AIDS and antiretroviral therapy. HIV AIDS 4, 117–124. doi: 10.2147/HIV.
S32321
Pasquau, J., Hidalgo-Tenorio, C., Montes, M. L., Romero-Palacios, A., Vergas, J.,
Sanjoaquin, I., et al. (2018). High quality of life, treatment tolerability, safety
and efficacy in HIV patients switching from triple therapy to lopinavir/ritonavir
monotherapy: a randomized clinical trial. PLoS One 13:e0195068. doi: 10.1371/
journal.pone.0195068
Rogers, S. (2015). Health Related Quality of Life Among Antiretroviral Therapy
(ART) Experienced and ART Naive Adults Attending an Urban HIV Clinic in
Kampala, Uganda. Available at: https://news.mak.ac.ug/documents/Makfiles/
theses/Sekabira_Robert.pdf
Rwegerera, G. M., Moshomo, T., Gaenamong, M., Oyewo, T. A., Gollakota, S.,
Mhimbira, F. A., et al. (2018). Antidiabetic medication adherence and
associated factors among patients in botswana; implications for the future.Alex.
J. Med. 54, 103–109. doi: 10.1016/j.ajme.2017.01.005
Saez-Llorens, X., Castano, E., Rathore, M., Church, J., Deville, J., Gaur, A., et al.
(2015). A randomized, open-label study of the safety and efficacy of switching
stavudine or zidovudine to tenofovir disoproxil fumarate in HIV-1-infected
children with virologic suppression. Pediatr. Infect. Dis. J. 34, 376–382. doi:
10.1097/INF.0000000000000289
Subbaraman, R., Chaguturu, S. K., Mayer, K. H., Flanigan, T. P., and
Kumarasamy, N. (2007). Adverse effects of highly active antiretroviral therapy
in developing countries. Clin. Infect. Dis. 45, 1093–1101. doi: 10.1086/521150
Vagiri, R. V., Meyer, J. C., and Gous, A. G. S. (2014). Satisfaction with aspects of
health-related quality of life (HRQoL) amongst HIV positive patients attending
a tertiary hospital clinic in South Africa. Afr. J. Phys. Health Educ. Recreat.
Dance 1, 22–31.
Vagiri, R. V., Meyer, J. C., and Gous, A. G. S. (2015). Health-related quality of life
and adherence to antiretroviral treatment over a 12-month period for patients
attending two public sector clinics in South Africa. Afr. J. Phys. Health Edu.
Recreat. Dance 2, 228–240.
Van Tam, V., Larsson, M., Pharris, A., Diedrichs, B., Nguyen, H. P., Nguyen, C. T.,
et al. (2012). Peer support and improved quality of life among persons living
withHIV on antiretroviral treatment: a randomised controlled trial from north-
eastern Vietnam. Health Qual. Life Outcomes 10:53. doi: 10.1186/1477-7525-
10-53
Velen, K., Lewis, J. J., Charalambous, S., Grant, A. D., Churchyard, G. J.,
and Hoffmann, C. J. (2013). Comparison of tenofovir, zidovudine, or
stavudine as part of first-line antiretroviral therapy in a resource-limited-
setting: a cohort study. PLoS One 8:e64459. doi: 10.1371/journal.pone.006
4459
von Wyl, V., Cambiano, V., Jordan, M. R., Bertagnolio, S., Miners, A., Pillay, D.,
et al. (2012). Cost-effectiveness of tenofovir instead of zidovudine for use in
first-line antiretroviral therapy in settings without virological monitoring. PLoS
One 7:e42834. doi: 10.1371/journal.pone.0042834
Waheed, S., Attia, D., Estrella, M. M., Zafar, Y., Atta, M. G., Lucas, G. M.,
et al. (2015). Proximal tubular dysfunction and kidney injury associated with
tenofovir in HIV patients: a case series. Clin. Kidney J. 8, 420–425. doi: 10.1093/
ckj/sfv041
Wandeler, G., Gerber, F., Rohr, J., Chi, B. H., Orrell, C., Chimbetete, C., et al.
(2014). Tenofovir or zidovudine in second-line antiretroviral therapy after
stavudine failure in southern Africa. Antivir. Ther. 19, 521–525. doi: 10.3851/
IMP2710
Wang, H., Wolock, T. M., Carter, A., Nguyen, G., Kyu, H. H., Gakidou, E., et al.
(2016). Estimates of global, regional, and national incidence, prevalence, and
mortality of HIV, 1980-2015: the global burden of disease study 2015. Lancet
HIV 3, e361–e387. doi: 10.1016/S2352-3018(16)30087-X
Wang,W., Xiao, C., Yao, X., Yang, Y., Yan, H., and Li, S. (2018). Psychosocial health
and suicidal ideation among people living with HIV/AIDS: a cross-sectional
study in Nanjing, China. PLoS One 13:e0192940. doi: 10.1371/journal.pone.
0192940
WHO Constitution of The World Health Organization. (2006). Constitution of the
World Health Organization Basic Documents, 45th Edn. Geneva: WHO.
Wouters, E., Van Loon, F., Van Rensburg, D., and Meulemans, H. (2009). State of
the ART: clinical efficacy and improved quality of life in the public antiretroviral
therapy program, Free State province, South Africa. AIDS Care 21, 1401–1411.
doi: 10.1080/09540120902884034
Wu, A. W., Revicki, D. A., Jacobson, D., and Malitz, F. E. (1997). Evidence for
reliability, validity and usefulness of the medical outcomes study HIV Health
Survey (MOS-HIV). Qual. Life Res. 6, 481–493. doi: 10.1023/A:101845193
0750
Wu, A. W., Rubin, H. R., Mathews, W. C., Ware, J. E. Jr., Brysk, L. T., Hardy,
W. D., et al. (1991). A health status questionnaire using 30 items from
the Medical Outcomes Study. preliminary validation in persons with early
HIV infection. Med. Care 29, 786–798. doi: 10.1097/00005650-199108000-
00011
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2018 Etenyi, Okalebo, Oluka, Sinei, Osanjo, Kurdi, Meyer, Godman and
Opanga. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in
other forums is permitted, provided the original author(s) and the copyright owner(s)
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org 14 October 2018 | Volume 9 | Article 984
